Clinical Outcomes in Carbapenem-Resistant Enterobacteriaceae Infections Treated With Ceftazidime-Avibactam: A Single-Center Observational Study

Introduction Among the several newer beta lactam+beta lactase inhibitors (BL/BLI), ceftazidime-avibactam is the only drug showing activity against OXA-48-like producers. Hence, it is being increasingly used in India to treat infections caused by carbapenem-resistant Enterobacteriaceae (CRE), especia...

Descripción completa

Detalles Bibliográficos
Autores principales: Rathish, Balram, Wilson, Arun, Warrier, Anup, Prakash, Shilpa, Babu, Rachana, Joy, Sonya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Infectious Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931974/
https://www.ncbi.nlm.nih.gov/pubmed/33680621
http://dx.doi.org/10.7759/cureus.13081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931974/
https://www.ncbi.nlm.nih.gov/pubmed/33680621
http://dx.doi.org/10.7759/cureus.13081

Ejemplares similares